Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.47 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.47 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | MAN2B1 | O00754 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7612049 | 1.00 | TDP1 (0.51) | TDP1TPSAB1TPSD1TPSG1MAOA | |
| SCHEMBL22431353 | 1.00 | TDP1 (0.51) | TDP1TPSAB1TPSD1TPSG1MAOA | |
| SCHEMBL17381378 | 1.00 | TDP1 (0.51) | TDP1TPSAB1TPSD1TPSG1MAOA | |
| SCHEMBL17468120 | 0.99 | TDP1 (0.49) | TDP1TPSAB1TPSD1TPSG1MAOA | |
| SCHEMBL22402873 | 0.95 | TDP1 (0.47) | TDP1TPSAB1TPSD1TPSG1MAOA | |
| SCHEMBL3474501 | 0.95 | TDP1 (0.47) | TDP1TPSAB1TPSD1TPSG1MAOA | |
| SCHEMBL3402806 | 0.95 | TDP1 (0.47) | TDP1TPSAB1TPSD1TPSG1MAOA | |
| SCHEMBL3122796 | 0.89 | ALDH1A1 (0.44) | TDP1MAOAMAOBMAN2B1MEN1 | |
| SCHEMBL17589281 | 0.88 | CA12 (0.38) | TDP1TPSAB1TPSD1TPSG1MAN2B1 | |
| SCHEMBL13497900 | 0.88 | CYP3A4 (0.43) | TDP1TPSAB1TPSD1TPSG1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6615842-B1 | Methods for removing nucleophilic toxins from tobacco smoke | CERAMI CONSULTING CORP. | 2003-09-09 | — | — | US | claimed |
| US-6119701-A | USING A FILTER ELEMENT COMPRISING A POLYMER DERIVATIZED WITH ALDEHYDIC GROUPS, E.G., CELLULOSE DIALDEHYDE, DIALDEHYDE STARCHES; DETOXIFICATION WITHOUT REMOVAL OF THE NICOTINE AND FLAVOR; CIGARETTES, CIGARS, PIPES AND ROOM AIR FILTERS | CERAMI CONSULTING CORP. (US) | 2000-09-19 | — | — | US | claimed |
| US-20250276074-A1 | BRM AND BRG1 TARGETING ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | PRELUDE THERAPEUTICS INCORPORATED | 2025-09-04 | — | — | US | disclosed |
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2025-06-05 | — | — | US | disclosed |
| WO-2025042899-A2 | METHODS FOR IDENTIFYING COMPOUNDS BINDING TO A TARGET MOLECULE USING MIRROR-IMAGING OF THE TARGET MOLECULE | X-CHEM, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| WO-2025042989-A1 | PSMA-BASED ALBUMIN BINDING AGENTS FOR TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-02-27 | — | — | WO | disclosed |
| CN-118146170-A | High affinity agents for prostate specific membrane antigen targeting for intracavity radiation therapy of prostate cancer | 约翰霍普金斯大学 | 2024-06-07 | — | — | CN | disclosed |
| EP-4364754-A2 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| CN-111032632-B | High affinity agents for prostate specific membrane antigen targeting for intracavity radiation therapy of prostate cancer | 约翰霍普金斯大学 | 2024-04-12 | — | — | CN | disclosed |
| US-20240058450-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2024-02-22 | — | — | US | disclosed |
| US-5859210-A | Boronic compound complexing reagents and complexes | PROLINX, INC. (US) | 1999-01-12 | — | — | US | disclosed |
| US-5847192-A | Boronic compound complexing reagents and complexes | PROLINX, INC. (US) | 1998-12-08 | — | — | US | disclosed |
| US-5837878-A | Boronic compound complexing reagents and highly stable complexes | PROLINX, INC. (US) | 1998-11-17 | — | — | US | disclosed |
| US-5777148-A | Boronic compound complexing reagents and highly stable complexes | PROLINX, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| US-5744627-A | Boronic compound complexing reagents and complexes | PROLINX, INC. (US) | 1998-04-28 | — | — | US | disclosed |
| US-5667764-A | USEFUL IN TREATMENT OF POST-ANGIOPLASTY RESTENOSIS, RHEUMATOID ARTHRITIS, TUMOR CELL PROLIFERATION AND PSORIASIS | ZYNAXIS, INC. (US) | 1997-09-16 | — | — | US | disclosed |
| EP-0643706-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR BINDING BIO-AFFECTING SUBSTANCES TO SURFACE MEMBRANES OF BIO-PARTICLES | Zynaxis Inc. (US) | 1995-03-22 | — | — | EP | disclosed |
| EP-0643706-A4 | COMPOUNDS, COMPOSITIONS AND METHODS FOR BINDING BIO-AFFECTING SUBSTANCES TO SURFACE MEMBRANES OF BIO-PARTICLES. | ZYNAXIS INC (US) | 1994-12-27 | — | — | EP | disclosed |
| WO-1993011120-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR BINDING BIO-AFFECTING SUBSTANCES TO SURFACE MEMBRANES OF BIO-PARTICLES | ZYNAXIS TECHNOLOGIES, INCORPORATED (US) | 1993-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | TDP1 4598/4885TPSAB1 3570/4885TPSD1 4588/4885 |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | TDP1 3899/4885TPSAB1 4597/4885TPSD1 4798/4885 |
| US-20250276074-A1 | BRM AND BRG1 TARGETING ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | CRBN, RBX1, SMARCE1 | TDP1 1478/4885TPSAB1 4498/4885TPSD1 4816/4885 |
| US-20240058450-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | TDP1 3899/4885TPSAB1 4597/4885TPSD1 4798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.